Jane Street
BTAI icon

Jane Street’s BioXcel Therapeutics BTAI Stock Holding History

Jane Street’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-794
Closed -$32.1K – 9209
2023
Q3 		$32.1K Sell
794
-12,212
-94% -$1.23M ﹤0.01% 8235
2023
Q2 		$1.39M Buy
+13,006
New +$4.33M ﹤0.01% 4701
2021
Q4 		– Sell
-675
Closed -$328K – 10088
2021
Q3 		$328K Sell
675
-363
-35% -$160K ﹤0.01% 8012
2021
Q2 		$482K Sell
1,038
-1,075
-51% -$586K ﹤0.01% 7310
2021
Q1 		$1.46M Buy
2,113
+163
+8% +$131K ﹤0.01% 4672
2020
Q4 		$1.44M Sell
1,950
-1,494
-43% -$1.16M ﹤0.01% 4067
2020
Q3 		$2.39M Buy
3,444
+2,969
+625% +$2.23M ﹤0.01% 2777
2020
Q2 		$403K Buy
+475
New +$310K ﹤0.01% 5393

Other funds holding BTAI

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Jane Street's BTAI Position: Q1 2026 in Review

Jane Street sold out of BioXcel Therapeutics (BTAI) in Q1 2026, closing a stake of 127,501 shares — an estimated $204K sold.

Jane Street first reported a position in BTAI in Q1 2020 and held it in 18 quarters. The position peaked at $3.15M in Q3 2020. 40 funds tracked by Wall St. Rank hold BTAI as of Q1 2026.

  • Jane Street reported no remaining BioXcel Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Jane Street sold 127,501 BioXcel Therapeutics shares in Q1 2026, an estimated $204K.
  • Jane Street first reported a position in BioXcel Therapeutics in Q1 2020 and held it in 18 quarters.
  • Jane Street's BioXcel Therapeutics position peaked at $3.15M in Q3 2020.
  • 40 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.